Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment

Fineline Cube Apr 10, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National...

Company Legal / IP

Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA

Fineline Cube Apr 7, 2023

Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by...

Company Deals Digital

ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray

Fineline Cube Apr 7, 2023

Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership,...

Policy / Regulatory

China’s Provincial Governments Implement Second Batch of National Drug Use Monitoring Policy

Fineline Cube Apr 7, 2023

In line with a notification issued by the National Health Commission (NHC) in January, provincial...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study

Fineline Cube Apr 7, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light...

Company Medical Device

AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use

Fineline Cube Apr 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Deals

Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia

Fineline Cube Apr 7, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian...

Company Deals

Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta

Fineline Cube Apr 7, 2023

Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...

Company Deals

Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product

Fineline Cube Apr 7, 2023

China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech...

Company Drug

Vcanbio Receives CDE Approval for VUM02 Clinical Trial in Idiopathic Pulmonary Fibrosis

Fineline Cube Apr 7, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Deals

Luye Pharma Group Partners with Duopharma for Exclusive Marketing Rights of TCM in Malaysia

Fineline Cube Apr 7, 2023

China-based Luye Pharma Group (HKG: 2186) has signed an agreement with Malaysia’s Duopharma Marketing Sdn...

Company Deals

Scorpion Therapeutics and Pierre Fabre Collaborate on NSCLC Therapies STX-721 and STX-241

Fineline Cube Apr 7, 2023

US-based Scorpion Therapeutics Inc. has formed a collaboration and license deal with France-based Pierre Fabre,...

Company Deals

Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China

Fineline Cube Apr 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district...

Company Drug

Haisco Pharmaceutical Gets CDE Approval for HSK38008 Prostate Cancer Clinical Study

Fineline Cube Apr 6, 2023

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving approval from the Center for...

Company Drug

Yiling Pharmaceutical’s G201-Na Receives CDE Approval for Phase Ia Study in Prostate Cancer Treatment

Fineline Cube Apr 6, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for...

Company Drug

Mabwell’s 9MW2821 ADC Shows Positive Signals in Solid Tumor Clinical Data

Fineline Cube Apr 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced preliminary clinical data for its...

Company Deals R&D

Gates Foundation and NSFC Launch Partnership to Boost Regulatory Science in Vaccine Development

Fineline Cube Apr 6, 2023

The Bill & Melinda Gates Foundation (Gates Foundation) and the National Natural Science Foundation of...

Company Drug

AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital

Fineline Cube Apr 6, 2023

AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...

Policy / Regulatory

Provincial Budgets Highlight Top Earning Hospitals in China for 2023

Fineline Cube Apr 6, 2023

Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a...

Company Drug

Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan

Fineline Cube Apr 6, 2023

Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...

Posts pagination

1 … 540 541 542 … 666

Recent updates

  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
  • China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Company

Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.